Lavinia P. Middleton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lavinia P. Middleton has a total of 461 co-authors. Here are the top co-authors by number of shared publications:
Kelly K. Hunt
Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
11 shared publicationsGeorge H. Perkins
Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
10 shared publicationsNour Sneige
Department of Pathology The University of Texas MD Anderson Cancer Center Houston Texas
10 shared publications- Aysegul A. Sahin
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9 shared publications Aysegul A. Sahin
Department of Pathology; The University of Texas MD Anderson Cancer Center; Houston Texas
8 shared publicationsGabriel N. Hortobagyi
Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
8 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Elsevier in Human Pathology
Germline cancer predisposition gene mutations and upgrade rate to breast cancer among patients with pleomorphic and florid lobular carcinoma in situ
- 18 September 2026
- Published by Elsevier in Human Pathology
Open AccessGermline cancer predisposition gene mutations and upgrade rate to breast cancer among patients with pleomorphic and florid lobular carcinoma in situ
- Open Access
- 27 August 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (9) , 193-198
The Effect of Germline Pathogenic Variants in the Upgrade Rate to Breast Cancer Among Patients Diagnosed With Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ on Core Needle Biopsy
- 27 August 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (9) , 193-198
Open AccessThe Effect of Germline Pathogenic Variants in the Upgrade Rate to Breast Cancer Among Patients Diagnosed With Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ on Core Needle Biopsy
- 30 September 2025
- Published by Wiley in Histopathology
- Vol. 88 (2) , 524-532
TRPS1 expression in neuroendocrine neoplasms of breast and other organs
Background: Primary neuroendocrine (NE) neoplasms of the breast are rare. In the absence of in situ carcinoma, metastasis from other organs needs to be ruled out first. TRPS1 is a recently identified marker for breast origin. In the current study, we investigated TRPS1 expression in breast neuroendocrine neoplasms, including well‐differentiated neuroendocrine tumour (NET) and poorly differentiated neuroendocrine carcinoma (NEC), and compared its expression with neuroendocrine neoplasms from other organs, such as lung, gastrointestinal tract and pancreas. Methods and results: A total of 105 cases of NE neoplasms were included in our study cohort, including 56 from breast (39 NETs and 17 NECs), 18 from lung (12 typical and atypical carcinoids, and 6 NECs), 19 from gastrointestinal tract (10 NETs, 3 NECs, 6 NETs metastases to breast) and 12 from pancreas (9 NETs, 3 NECs). TRPS1 exhibited moderate to strong expression in 38 of 39 breast NETs (97.4%). Four of 17 (23.5%) breast NECs showed weak to moderate staining. By contrast, no TRPS1 staining was observed in any of the 18 lung and 12 pancreatic NE neoplasms. Among 19 gastrointestinal NE neoplasms, only 1 NEC displayed scattered low TRPS1 positivity. Conclusions: Our study demonstrated that TRPS1 is universally expressed in mammary NET, and it is a valuable marker to distinguish primary mammary NET from metastatic NET of other organs, including lung, gastrointestinal tract and pancreas. TRPS1 has limited utility in differentiating mammary NEC from NEC of other organs. Clinical radiographic correlation is paramount in diagnosing primary NEC of the breast.
- 30 September 2025
- Published by Wiley in Histopathology
- Vol. 88 (2) , 524-532
TRPS1 expression in neuroendocrine neoplasms of breast and other organs
Background: Primary neuroendocrine (NE) neoplasms of the breast are rare. In the absence of in situ carcinoma, metastasis from other organs needs to be ruled out first. TRPS1 is a recently identified marker for breast origin. In the current study, we investigated TRPS1 expression in breast neuroendocrine neoplasms, including well‐differentiated neuroendocrine tumour (NET) and poorly differentiated neuroendocrine carcinoma (NEC), and compared its expression with neuroendocrine neoplasms from other organs, such as lung, gastrointestinal tract and pancreas. Methods and results: A total of 105 cases of NE neoplasms were included in our study cohort, including 56 from breast (39 NETs and 17 NECs), 18 from lung (12 typical and atypical carcinoids, and 6 NECs), 19 from gastrointestinal tract (10 NETs, 3 NECs, 6 NETs metastases to breast) and 12 from pancreas (9 NETs, 3 NECs). TRPS1 exhibited moderate to strong expression in 38 of 39 breast NETs (97.4%). Four of 17 (23.5%) breast NECs showed weak to moderate staining. By contrast, no TRPS1 staining was observed in any of the 18 lung and 12 pancreatic NE neoplasms. Among 19 gastrointestinal NE neoplasms, only 1 NEC displayed scattered low TRPS1 positivity. Conclusions: Our study demonstrated that TRPS1 is universally expressed in mammary NET, and it is a valuable marker to distinguish primary mammary NET from metastatic NET of other organs, including lung, gastrointestinal tract and pancreas. TRPS1 has limited utility in differentiating mammary NEC from NEC of other organs. Clinical radiographic correlation is paramount in diagnosing primary NEC of the breast.
- 10 July 2025
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 213 (2) , 225-235
Immediate and ipsilateral recurrence rates and treatment recommendations for patients with pleomorphic and florid lobular carcinoma in situ
Background Follow-up data are limited regarding the natural history of patients diagnosed with pleomorphic lobular carcinoma in situ (PLCIS) and florid lobular carcinoma in situ (FLCIS). Methods This retrospective study identified patients with PLCIS and FLCIS. Clinicopathologic findings were evaluated. Patients with concurrently diagnosed ipsilateral breast cancer or ductal carcinoma in situ were excluded. The immediate and delayed risk of developing breast cancer was calculated. Results All 45 patients were female, and the median age was 61 years. The most common imaging finding was suspicious calcifications on screening mammogram in 84.4%. The histology was PLCIS in 75.6% of cases (34/45), FLCIS in 11.1% (5/45), and a combination of variant types in 13% (6/45). Forty-four patients underwent surgery to include wide local excision in 84% (37/44) and mastectomy in 15.9% (7/44). One patient (2.3%) had concurrent DCIS on excision and ten patients (22.7%) had diagnoses upgraded to invasive carcinoma on excision, the majority being T1a (70%) and the remainder T1b (30%). These aforementioned patients were excluded from further outcome analysis. There were four patients (8.8%) with PLCIS who developed ipsilateral cancers in the same quadrant; of which two were local and two were local regional occurring 135, 106, 89, and 60 months after the initial diagnosis. All four patients had < 2 mm margins after initial surgery (p < 0.05). Conclusions There is both an immediate (24.4%) and delayed (8.8%) risk of breast cancer in patients diagnosed with PLCIS and FLCIS. Our data support excision to 2 mm margin and maintenance of long-term follow-up.
- 10 July 2025
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 213 (2) , 225-235
Immediate and ipsilateral recurrence rates and treatment recommendations for patients with pleomorphic and florid lobular carcinoma in situ
Background Follow-up data are limited regarding the natural history of patients diagnosed with pleomorphic lobular carcinoma in situ (PLCIS) and florid lobular carcinoma in situ (FLCIS). Methods This retrospective study identified patients with PLCIS and FLCIS. Clinicopathologic findings were evaluated. Patients with concurrently diagnosed ipsilateral breast cancer or ductal carcinoma in situ were excluded. The immediate and delayed risk of developing breast cancer was calculated. Results All 45 patients were female, and the median age was 61 years. The most common imaging finding was suspicious calcifications on screening mammogram in 84.4%. The histology was PLCIS in 75.6% of cases (34/45), FLCIS in 11.1% (5/45), and a combination of variant types in 13% (6/45). Forty-four patients underwent surgery to include wide local excision in 84% (37/44) and mastectomy in 15.9% (7/44). One patient (2.3%) had concurrent DCIS on excision and ten patients (22.7%) had diagnoses upgraded to invasive carcinoma on excision, the majority being T1a (70%) and the remainder T1b (30%). These aforementioned patients were excluded from further outcome analysis. There were four patients (8.8%) with PLCIS who developed ipsilateral cancers in the same quadrant; of which two were local and two were local regional occurring 135, 106, 89, and 60 months after the initial diagnosis. All four patients had < 2 mm margins after initial surgery (p < 0.05). Conclusions There is both an immediate (24.4%) and delayed (8.8%) risk of breast cancer in patients diagnosed with PLCIS and FLCIS. Our data support excision to 2 mm margin and maintenance of long-term follow-up.
- 30 June 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (5) , 993-1002
Pattern of SOX9 expression in pleomorphic adenoma, carcinoma ex pleomorphic adenoma, and matrix-producing metaplastic carcinoma of the breast lends support to common biology
In the salivary gland, the diagnosis of pleomorphic adenoma (PA) and carcinoma ex pleomorphic adenoma (CXPA) is not difficult, but when these entities occur in the breast, they produce challenges in diagnosis and in the differential diagnosis of mesenchymal/matrix-producing metaplastic carcinoma (MpMC). The study of these rare entities provides insight into the development of MpMC and potentially provides direction for therapeutic targets. Three cases of mammary CXPA were compared histologically and immunohistochemically with 35 cases of MpMC as well as 3 cases of PA. Evaluation of SOX9, a master regulator of chondrogenesis, was conducted in tissue sections of the tumors. All cases of CXPA of the breast were similar, demonstrating a nodule of tumor partially encased in a thick hyalinized sclerotic wall with central sclerosis. Well-defined ductular structures residing in a myxoid-chondroid stroma were identified. The malignant epithelial and myoepithelial components were distinctly more cellular than the central nidus of the PA and had peripheral expansion beyond the hyalinized pseudo-capsule of the tumor. In comparison, all MpMCs showed solid, bosselated equally distributed expansile hypercellular nests of cells within a dense myxoid and myxoid hyalinized stroma. Tumors showed a varying intensity of nuclear SOX9 staining in 100% of PA and CXPA and 31 (88.6%) MpMCs. Two of the four SOX9 negative MpMC cases showed osseous differentiation. SOX9 expression in tumors with heterologous mesenchymal differentiation can aid in establishing the diagnosis of PA, mammary CXPA, and chondroid MpMC.
- 30 June 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (5) , 993-1002
Pattern of SOX9 expression in pleomorphic adenoma, carcinoma ex pleomorphic adenoma, and matrix-producing metaplastic carcinoma of the breast lends support to common biology
In the salivary gland, the diagnosis of pleomorphic adenoma (PA) and carcinoma ex pleomorphic adenoma (CXPA) is not difficult, but when these entities occur in the breast, they produce challenges in diagnosis and in the differential diagnosis of mesenchymal/matrix-producing metaplastic carcinoma (MpMC). The study of these rare entities provides insight into the development of MpMC and potentially provides direction for therapeutic targets. Three cases of mammary CXPA were compared histologically and immunohistochemically with 35 cases of MpMC as well as 3 cases of PA. Evaluation of SOX9, a master regulator of chondrogenesis, was conducted in tissue sections of the tumors. All cases of CXPA of the breast were similar, demonstrating a nodule of tumor partially encased in a thick hyalinized sclerotic wall with central sclerosis. Well-defined ductular structures residing in a myxoid-chondroid stroma were identified. The malignant epithelial and myoepithelial components were distinctly more cellular than the central nidus of the PA and had peripheral expansion beyond the hyalinized pseudo-capsule of the tumor. In comparison, all MpMCs showed solid, bosselated equally distributed expansile hypercellular nests of cells within a dense myxoid and myxoid hyalinized stroma. Tumors showed a varying intensity of nuclear SOX9 staining in 100% of PA and CXPA and 31 (88.6%) MpMCs. Two of the four SOX9 negative MpMC cases showed osseous differentiation. SOX9 expression in tumors with heterologous mesenchymal differentiation can aid in establishing the diagnosis of PA, mammary CXPA, and chondroid MpMC.
- Open Access
- 3 August 2024
- Published by Elsevier in Human Pathology Reports
- Vol. 37
Characteristics of secretory breast carcinoma with extensive in situ carcinoma components: Clinical and histopathologic analysis
- 3 August 2024
- Published by Elsevier in Human Pathology Reports
- Vol. 37
Open AccessCharacteristics of secretory breast carcinoma with extensive in situ carcinoma components: Clinical and histopathologic analysis
- 12 March 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 205 (3) , 545-554
Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants
Objective To determine the risk of breast cancer due to lobular carcinoma in situ (LCIS). Methods This retrospective IRB-approved study identified cases of LCIS after percutaneous breast biopsy from 7/2005 to 7/2022. Excluded were cases with less than 2 years of imaging surveillance or a concurrent ipsilateral breast cancer diagnosis within 6 months of the LCIS diagnosis. Final outcomes of cancer versus no cancer were determined by pathology at surgical excision or the absence of cancer on imaging surveillance. Results A total of 116 LCIS lesions were identified. The primary imaging findings targeted for percutaneous biopsy included calcifications (50.0%, 58/116), MR enhancing lesions (25.0%, 29/116), noncalcified mammographic architectural distortions (10.3%, 12/116), or masses (14.7%, 17/116). Surgical excision was performed in 49.1% (57/116) and imaging surveillance was performed in 50.9% (59/116) of LCIS cases. There were 22 cancers of which 11 cancers were discovered at immediate excision [19.3% (11/57) immediate upgrade] and 11 cancers developed later while on imaging surveillance [18.6% (11/59) delayed risk for cancer]. Among all 22 cancers, 63.6% (14/22) occurred at the site of LCIS (11 at immediate excision and 3 at surveillance) and 36.4% (8/22) occurred at a location away from the site of LCIS (6 in a different quadrant and 2 in the contralateral breast). Conclusion LCIS has both an immediate risk (19.3%) and a delayed risk (18.6%) for cancer with 90.9% occurring in the ipsilateral breast (63.6% at and 27.3% away from the site of LCIS) and 9.1% occurring in the contralateral breast.
- 12 March 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 205 (3) , 545-554
Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants
Objective To determine the risk of breast cancer due to lobular carcinoma in situ (LCIS). Methods This retrospective IRB-approved study identified cases of LCIS after percutaneous breast biopsy from 7/2005 to 7/2022. Excluded were cases with less than 2 years of imaging surveillance or a concurrent ipsilateral breast cancer diagnosis within 6 months of the LCIS diagnosis. Final outcomes of cancer versus no cancer were determined by pathology at surgical excision or the absence of cancer on imaging surveillance. Results A total of 116 LCIS lesions were identified. The primary imaging findings targeted for percutaneous biopsy included calcifications (50.0%, 58/116), MR enhancing lesions (25.0%, 29/116), noncalcified mammographic architectural distortions (10.3%, 12/116), or masses (14.7%, 17/116). Surgical excision was performed in 49.1% (57/116) and imaging surveillance was performed in 50.9% (59/116) of LCIS cases. There were 22 cancers of which 11 cancers were discovered at immediate excision [19.3% (11/57) immediate upgrade] and 11 cancers developed later while on imaging surveillance [18.6% (11/59) delayed risk for cancer]. Among all 22 cancers, 63.6% (14/22) occurred at the site of LCIS (11 at immediate excision and 3 at surveillance) and 36.4% (8/22) occurred at a location away from the site of LCIS (6 in a different quadrant and 2 in the contralateral breast). Conclusion LCIS has both an immediate risk (19.3%) and a delayed risk (18.6%) for cancer with 90.9% occurring in the ipsilateral breast (63.6% at and 27.3% away from the site of LCIS) and 9.1% occurring in the contralateral breast.
- 1 December 2023
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 2 (12)
Pulmonary Tumor Thrombotic Microangiopathy in a Patient With Dyspnea and Triple-Negative Breast Cancer
- 1 December 2023
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 2 (12)
Pulmonary Tumor Thrombotic Microangiopathy in a Patient With Dyspnea and Triple-Negative Breast Cancer
- Open Access
- 8 August 2023
- Published by Elsevier in Human Pathology Reports
- Vol. 33
Primary porocarcinoma of the nipple with metastasis: A case report of a rare entity with molecular analysis and imaging correlation
- 8 August 2023
- Published by Elsevier in Human Pathology Reports
- Vol. 33
Open AccessPrimary porocarcinoma of the nipple with metastasis: A case report of a rare entity with molecular analysis and imaging correlation
- Open Access
- 31 July 2023
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 32 (4) , 796-802
Invasive Carcinoma With Skin Adnexal Trichilemmal Hair Follicular Differentiation Occurring in the Breast: A Case Report With Detailed Immunohistochemical and Molecular Analysis
Cutaneous-type adnexal tumors involving the breast are rare and create a diagnostic dilemma as they are often indistinguishable from primary mammary neoplasms. Tumors showing hair follicular differentiation are particularly challenging due to their rarity and the subtle appreciation of the intricate microanatomy of the hair follicle. We report a triple negative cutaneous-type adnexal carcinoma with follicular differentiation involving the breast to bring attention to the existence of these specialized group of tumors which should be managed differently from conventional triple negative carcinomas of the breast.
- 31 July 2023
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 32 (4) , 796-802
Open AccessInvasive Carcinoma With Skin Adnexal Trichilemmal Hair Follicular Differentiation Occurring in the Breast: A Case Report With Detailed Immunohistochemical and Molecular Analysis
Cutaneous-type adnexal tumors involving the breast are rare and create a diagnostic dilemma as they are often indistinguishable from primary mammary neoplasms. Tumors showing hair follicular differentiation are particularly challenging due to their rarity and the subtle appreciation of the intricate microanatomy of the hair follicle. We report a triple negative cutaneous-type adnexal carcinoma with follicular differentiation involving the breast to bring attention to the existence of these specialized group of tumors which should be managed differently from conventional triple negative carcinomas of the breast.